Memo Clarifies CMS Guidelines on Injectables


Injectable drugs should be covered by Medicare if beneficiaries administer them less than 50 percent of the time, according to a clarification on this issue by the Centers for Medicare and Medicaid services that's set to take effect Aug. 1.

The clarification aims to resolve CMS's ambiguity on injectable drugs. It came in a memo to regional private contractors that process Medicare claims, instructing them to reimburse users of the multiple sclerosis drug, Avonex, because it generally is not self-administered.

Until recently, Medicare has paid only for injectable drugs administered in a doctor's office, but not drugs that patients administer themselves.

Last year, Congress ruled that Medicare should cover injectables that are "not usually self-administered," but neglected to define the term "not usually."

As a result, Medicare contractors made different reimbursement decisions for the same drug.

Career Opportunities

HAP, a subsidiary of Henry Ford Health System, is a nonprofit health plan providing coverage to individuals, companies and organizations. This executive develops strategies to meet membership and revenue targets through products, pricing, market segmentation and advertising.  Aligns business among Business Development, Commercial Sales, Medicare and Public Sector Programs and Product Development. Seeks to enhance and be responsible for business development and expansion through the development of an effective product portfolio, strong interpersonal relationships and service excellence.

Apply via email to jfedder1@hfhs.org or online at http://p.rfer.us/HENRYFORDlXqAJA

Subscribe to Our Newsletters

Monthly table of contents

Be notified as each issue of Managed Care is available online.

Biweekly newsletter

Recent topics have included:

PTCommunity news

New drug approvals, clinical trials, drug management. Three times per week.